Just as the discovery of penicillin opened the floodgates to an array of bacteria-fighting antibiotics, our ever-growing knowledge about DNA and its quirks and flaws is leading to the production of many more drugs like PLX This is about identifying the cancer, knowing what its changes are and being able to follow it in ways we could never have dreamt of before. Professor Mark Stratton, director of the Wellcome Trust Sanger Institute believes we may have reached the 'end game' for understanding cancer A trial on cancer patients, including some Britons, is underway, and, if successful, the drug could be on the market in as little as a year.
GlaxoSmithKline is developing a similar compound.
This is a paradigm genetic cancer cure in the way we are going to treat melanoma. People alive today are four times more likely to get malignant melanoma than their grandparents were. Sunbed use, the proliferation of foreign holidays and a reluctance to wear sunscreen are blamed for the soaring numbers.
In a devastating blow for leukaemia sufferers, NICE has today ruled that the drug Ofatumumab is too expensive to be funded on the NHS, even though it could grant them an extra 14 months of life. Ministers have promised that the money will cover any medicine that has been recommended by a cancer specialist, even if it has been banned by NICE.
Share or comment on this article: Cancer's 'penicillin moment'? Gene targeting drug could herald 'end game' for disease Most watched News videos.